A5003196509- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Health Systems, Economic Evaluations, Quality of Life
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Urological Disorders and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Ovarian cancer diagnosis and treatment
- Abdominal Trauma and Injuries
- Medical Imaging Techniques and Applications
- Statistical Methods in Clinical Trials
- Nonmelanoma Skin Cancer Studies
- Optimal Experimental Design Methods
- Maternal and fetal healthcare
- Spinal Dysraphism and Malformations
- Autopsy Techniques and Outcomes
- Colorectal Cancer Treatments and Studies
- Brain Metastases and Treatment
Healthcare Improvement Scotland
2019-2023
Frontier Agriculture (United Kingdom)
2013-2022
University of Dundee
2019-2021
AstraZeneca (United Kingdom)
2020-2021
Genomics (United Kingdom)
2020
Université Libre de Bruxelles
2013-2018
Memorial Sloan Kettering Cancer Center
2013-2018
Institut Jules Bordet
2013-2018
Yale University
2013-2018
Breast International Group
2018
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In Adjuvant and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed early were randomly assigned to 1 year of T, L, sequence (T→L), or combination (L+T). The primary end point was disease-free survival...
Molecular imaging receives increased attention for selecting patients who will benefit from targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) enrolled 455 women with invasive human epidermal growth factor receptor 2 (HER2)–positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, their combination. Each anti-HER2 therapy was given alone 6 wk, followed by 12 wk the same plus...
Purpose Previous research has suggested that young age at diagnosis is an independent risk factor for breast cancer recurrence and death. No prior studies have adequately controlled human epidermal growth receptor 2 (HER2) status or anti-HER2 treatment. We sought to evaluate whether was a prognostic predictive in the HERA trial. Patients Methods used 2-year median follow-up data dichotomized 40 years its effect on outcomes women assigned trastuzumab 1 year observation. Results Of 1,703...
Medical education has been characterized in terms of points transition, which are accentuated by lack relevant prior experience and can lead to extreme positive negative emotions.Quantify the effect maturity on medical students' transitions into clinical environment identify how experiences transition might be improved.Eleven weeks after entering environment, 29 mature students (age over 21 at entry, median age 22) a horizontally-integrated, predominantly undergraduate problem-based...
Two randomized trials recently demonstrated that regional nodal irradiation (RNI) could reduce the risk of recurrence in early breast cancer; however, these were conducted pretrastuzumab era. Whether results are applicable to human epidermal growth factor receptor 2 (HER2)-positive cancer patients treated with anti-HER2-targeted therapy is unknown.This retrospective analysis was performed on node-positive who enrolled Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization phase III...
Aims: To determine the coverage of vaccine and antibiotic prophylaxis in splenectomised patients Scotland.Methods: Patients who had undergone splenectomy between 1 January 1988 31 December 1998 were identified.A questionnaire was sent to general practitioners validate status for these patients.Results: A total 974 living identified during study period.Information on available 708 (73%) 770 (79%) patients, respectively.Coverage pneumococcal (88%) higher than that Haemophilus influenza type b...
502 Background: Pre-specified 5-year analyses of the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) Trial defined in Amendments 11&12. Methods: From June 2007 to July 2011, 8381 patients (pts) were randomised from 946 sites 44 countries receive either L+T, T→L, L, or T. In due futility L arm was closed and is not included this analysis. The primary end point disease-free survival (DFS). Secondary objectives include treatment comparisons with respect...
Trastuzumab acts in part through the adaptive immune system. Previous studies showed that enrichment of immune-related gene expression was associated with improved outcomes HER2-positive (HER2+) breast cancer. However, role system response to lapatinib is not fully understood. Gene analysis performed 1,268 samples from North Central Cancer Treatment Group (NCCTG) N9831 and 244 NeoALTTO trial. In N9831, CD45 immune-subset signatures were significantly outcomes. We identified a novel 17-gene...
512 Background: In the neoadjuvant NeoALTTO trial dual HER2 blockade with lapatinib (L) plus trastuzumab (T) combined weekly paclitaxel significantly increased pathologic complete response rate (pCR) compared either anti-HER2 agent alone paclitaxel. At first analysis pts pCR had a better event free survival (EFS) and overall (OS) after median follow-up of 3.84 yrs. Methods: 455 operable HER2-positive breast cancer were randomized to receive L (n=154) 1500mg/day, T 4mg/kg loading dose...
Actinic keratosis (AK) is a common premalignant skin lesion that can progress to cutaneous squamous cell carcinoma (cSCC). Microwave therapy an established cancer treatment and has been used for plantar viral warts.To evaluate the efficacy feasibility of microwave as AK.Stage I was dose-setting study, in which seven participants had dielectric properties 12 thick 22 thin AKs assessed optimization dose Stage II. II randomized, internally controlled trial evaluating 179 11 patients (93...
511 Background: The predictive value of PIK3CA mutations in HER2+ BC has been shown conclusively. Data on subgroup analyses are lacking. Methods: We combined data from three studies evaluating as predictor for pCR: the neoadjuvant GEPAR (n = 504) (Loibl et al. JCO 2014), Neo-ALTTO study 355) (Majewski 2015) and CHERLOB 108) (ESMO 2014). Patients received either trastuzumab (T), lapatinib (L) or combination T/L addition to taxane-based chemotherapy. was genotyped tumor biopsies prior therapy....
577 Background: Trastuzumab (H) acts in part through adaptive immune system, whereas lapatinib (L) inhibition of HER2 signaling. Previous studies showed that enrichment immune-related genes was associated with improved outcome. However, the role system response to L or LH is not fully understood. Methods: NanoString used quantify mRNA 1,378 samples from N9831 trial: Arm A chemotherapy alone, arm B sequential H, and C concurrent H. Enrichment analysis performed on significant HR generate a...
508 Background: Adjuvant T plus chemotherapy improves disease-free survival (DFS) and overall (OS) vs. alone for pts with early stage HER2-positive breast cancer. We conducted a meta-analysis to estimate DFS OS small tumors (≤2cm) in the arms from 5 of 6 randomized adjuvant trastuzumab trials. Pts ≤2cm, 0 or 1 positive lymph nodes, hormone receptor (HR) disease had 5-year 91% 97% (O’Sullivan, SABCS 2013; abstract:1327). now plan conduct an additional assess efficacy compared no (≤2cm)....